News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Epic adds Northwell's firearm screening tool to patient safety workflows
Northwell Health's gun violence prevention screening tool is now built into Epic's EHR. The integration flags high-risk patients and distributes gun locks in real time during clinical encounters.
Community oncology clinic cuts drug ordering time by 75% with AI inventory system
Oklahoma Cancer Specialists reduced rebate payment delays by 35 days and gained visibility into 99% of rebate opportunities using AI-powered specialty drug management. Here's how independent practices can tighten cash flow and cut administrative work.
Taipei Veterans General Hospital Reaches EMRAM Level 7
Taipei Veterans General Hospital achieved EMRAM Level 7 certification, the highest standard for electronic medical record maturity in healthcare IT. What the milestone means for Asia-Pacific health systems.
Joint Commission certifies AI governance in hospitals, not the tools
Joint Commission launches a voluntary certification for healthcare organizations deploying AI safely. The program audits governance, data management, and transparency—not individual AI products.
Healthcare networks face data center strain from telemedicine and AI diagnostics
Health systems deploying telemedicine, AI diagnostics, and medical IoT devices are stressing data center capacity. Anritsu white paper outlines testing and monitoring strategies to maintain performance and compliance.
AbiVax drug shows best efficacy but cancer cases tank stock 30%
AbiVax's obefazimod delivered efficacy results analysts called best-in-disease for ulcerative colitis, but cancer cases reported in treatment recipients wiped out gains and sent shares down more than 30%.
Fulcrum's sickle cell drug stalled by FDA, company explores sale
Fulcrum Therapeutics faces an FDA setback on its sickle cell medicine and is exploring a potential sale. The stumble mirrors recent failures from Pfizer, Novartis, and Intellia in the same disease area.
Eli Lilly demands 340B hospitals prove drug discount compliance by Monday
Eli Lilly set a data-sharing deadline for select hospitals to demonstrate they're not exploiting federal drug discounts. Some facilities are pushing back, asking the government to intervene.
Celcuity breast cancer drug misses efficacy bar despite investor hype
Gedatolisib failed to meet primary endpoints in a pivotal PIK3CA-mutated breast cancer trial, deflating investor expectations despite investigator claims of potential standard-of-care status.
Lilly, Ascidian Strike $1.9B RNA Editing Deal for Kidney Disease
Eli Lilly partners with Ascidian Therapeutics in a deal worth up to $1.9 billion to develop RNA exon-editing treatments for genetic kidney diseases. What this means for the RNA therapeutics pipeline.
Healthcare consent rules lag other industries by years
Healthcare systems lack the consent flexibility that finance, retail, and tech have adopted. Two major conferences will tackle the gap between AI ambition and evidence-based deployment.
HIMSS Conferences Bring AI Healthcare From Theory to Clinical Practice
Two HIMSS events in 2026 will convene clinicians, technologists, and executives to bridge the gap between AI ambition and real-world deployment in healthcare systems across Asia-Pacific and Boston.